Yayın:
Characterization of changes in FibroTest values during treatment with tenofovir alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) in patients with CHB

Basit Görünüm
dc.contributor.authorIzumi, Namiki
dc.contributor.authorTsang, Owen Tak Yin
dc.contributor.authorAhn, Sang Hoon
dc.contributor.authorAngus, Peter W.
dc.contributor.authorFlaherty, John F.
dc.contributor.authorKim, Kyungpil
dc.contributor.authorGaggar, Anuj
dc.contributor.authorSuri, Vithika
dc.contributor.authorSubramanian, Mani
dc.contributor.authorCooper, Curtis
dc.contributor.authorHann, Hie-Won
dc.contributor.authorAcharya, Subrat K.
dc.contributor.buuauthorGürel, Selim
dc.contributor.departmentTıp Fakültesi
dc.contributor.researcheridHLH-8209-2023
dc.date.accessioned2023-05-17T07:04:33Z
dc.date.available2023-05-17T07:04:33Z
dc.date.issued2016-10
dc.descriptionBu çalışma, 11-15 Kasım 2016 tarihlerinde Boston[Amerika Birleşik Devletleri]’ da düzenlenen 67. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) Kongresi‘nde bildiri olarak sunulmuştur.
dc.description.sponsorshipAmer Assoc Study Liver Dis
dc.identifier.citationIzumi, N, vd. (2016). "Characterization of changes in FibroTest values during treatment with tenofovir alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) in patients with CHB". Hepatology, 64(Supplement 1), 941A-942A.
dc.identifier.endpage942A
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.issueSupplement 1
dc.identifier.startpage941A
dc.identifier.urihttps://www.natap.org/2016/AASLD/AASLD_92.htm
dc.identifier.urihttp://hdl.handle.net/11452/32689
dc.identifier.volume64
dc.identifier.wos000385493804264
dc.indexed.wosSCIE
dc.indexed.wosCPCIS
dc.language.isoen
dc.publisherWiley
dc.relation.collaborationYurt dışı
dc.relation.collaborationSanayi
dc.relation.journalHepatology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGastroenterology & hepatology
dc.subject.wosGastroenterology & hepatology
dc.titleCharacterization of changes in FibroTest values during treatment with tenofovir alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) in patients with CHB
dc.typeOther
dc.type.subtypeMeeting Abstract
dc.wos.quartileQ1
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama
İndir

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications